Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

24.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
MicroRNAs01:22

MicroRNAs

4.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Vaccinations01:51

Vaccinations

51.7K
Overview
51.7K
Transcription Attenuation in Prokaryotes02:42

Transcription Attenuation in Prokaryotes

18.5K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure.  Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.5K
What are Viruses?00:50

What are Viruses?

128.2K
Overview
128.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans.

mBio·2026
Same author

The Vertebrate Genomes Project Phase I: A global reference genome resource.

bioRxiv : the preprint server for biology·2026
Same author

Intrinsic OASL expression governs heterogeneity in interferon induction during influenza A virus infection.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Does fever drive the evolution of antiviral genes?

The Journal of experimental medicine·2025
Same author

Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza.

The Journal of experimental medicine·2025
Same author

Mammalian antiviral proteins ZAP and KHNYN can independently restrict CpG-enriched avian viruses.

PLoS biology·2025

Related Experiment Video

Updated: Feb 4, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

MicroRNA-Attenuated Virus Vaccines.

Elizabeth J Fay1,2, Ryan A Langlois3,4,5

  • 1Biochemistry, Molecular Biology, and Biophysics Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA. fayxx084@umn.edu.

Non-Coding RNA
|October 4, 2018
PubMed
Summary

Live-attenuated vaccines offer strong immunity but pose safety risks. Engineering viruses with host microRNAs (miRNAs) enhances vaccine safety and stability, creating promising vaccine candidates.

Keywords:
RNAilive-attenuated vaccinesiRNA

More Related Videos

Potato Virus X-Based microRNA Silencing VbMS In Potato.
11:51

Potato Virus X-Based microRNA Silencing VbMS In Potato.

Published on: May 11, 2020

3.6K
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.2K

Related Experiment Videos

Last Updated: Feb 4, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Potato Virus X-Based microRNA Silencing VbMS In Potato.
11:51

Potato Virus X-Based microRNA Silencing VbMS In Potato.

Published on: May 11, 2020

3.6K
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.2K

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Live-attenuated vaccines are highly effective but carry risks of reversion to pathogenic wild-type viruses.
  • Host-derived microRNAs (miRNAs) offer a novel strategy for viral attenuation.

Purpose of the Study:

  • To review methods for engineering miRNA-attenuated viruses.
  • To discuss strategies for enhancing the safety and stability of these viral vaccines.
  • To explore the potential of miRNA-attenuated viruses as vaccine candidates.

Main Methods:

  • Engineering viruses by incorporating host-derived microRNAs (miRNAs) for attenuation.
  • Developing strategies to improve the safety and stability of miRNA-attenuated viruses.
  • Reviewing existing literature on miRNA-based viral attenuation for vaccine development.

Main Results:

  • miRNA-attenuated viruses demonstrate potential for robust, long-lasting immunity.
  • Tailored targeting using specific miRNAs allows for precise attenuation strategies.
  • Strategies exist to mitigate concerns regarding viral escape and improve vaccine safety.

Conclusions:

  • miRNA-mediated attenuation presents a promising approach to developing safer and more effective live-attenuated viral vaccines.
  • Further research into miRNA-attenuated viruses could lead to next-generation vaccines with improved safety profiles.
  • The adaptability of miRNA targeting offers a versatile platform for vaccine design against various viruses.